TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Adial Pharmaceuticals Announces Publication of International PCT Patent Application to Protect Core Assets and Extend IP Exclusivity to at least 2045

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Na
Adial Pharmaceuticals Announces Publication of International PCT Patent Application to Protect Core Assets and Extend IP Exclusivity to at least 2045

Adial Pharmaceuticals announced the publication of an international patent application for AD04, its lead investigational drug for treating Alcohol Use Disorder in heavy drinking patients. The patent, once granted, is expected to protect the company's core assets through at least 2045. The patent application is based on treatment of populations identified as particularly responsive to ondansetron treatment following examination of Adial's clinical data.

Insights
NKE   neutral

Mentioned as a retail partner without specific performance details


ADIL   positive

The company secured patent protection extending IP exclusivity to 2045 for its lead drug candidate AD04, which strengthens its competitive moat and provides long-term protection for core assets. The company is advancing clinical development with planning for the next phase of trials, demonstrating progress in its pipeline.